Table 1 Characteristics of manuscripts studied and outcome series extracted (Continued)

Colorectal cancer

1 (0.6%)

1 (1.1%)

Gynaecological cancer

1 (0.6%)

1 (1.1%)

B-cell malignancies

0 (0%)

1 (1.1%)

Not disclosed

1 (0.6%)

0 (0%)

Pancreatic cancer

1 (0.6%)

0 (0%)

Rectal cancer

1 (0.6%)

0 (0%)

Treatment undergoing dose-escalation

Inhibitor

58 (37%)

43 (46%)

Chemotherapy

51 (33%)

25 (27%)

Chemotherapy + inhibitor

17 (11%)

12 (13%)

Monoclonal antibody

8 (5.2%)

0 (0.0%)

Immunomodulatory

4 (2.6%)

2 (2.2%)

Immunomodulatory + chemotherapy

3 (1.9%)

2 (2.2%)

Radiotherapy

4 (2.6%)

1 (1.1%)

Oncolytic virus

2 (1.3%)

2 (2.2%)

Radiopharmaceutical + inhibitor

2 (1.3%)

2 (2.2%)

Cell therapy

1 (0.6%)

2 (2.2%)

Antibody-drug conjugate

1 (0.6%)

1 (1.1%)

Cytokine

1 (0.6%)

1 (1.1%)

Chemoprevention

1 (0.6%)

0 (0%)

Gene therapy

1 (0.6%)

0 (0%)

Not disclosed

1 (0.6%)

0 (0%)

Treatment ensemble contains chemotherapy

91 (59%)

49 (53%)

Number of dose-levels

4 (2, 5)

4 (2, 5)